Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL
Acalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia.
Acalabrutinib Calquence Acalabrutinib And Zanubrutinib Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Ascend Trial Alpine Trial
Source: onclive.com